A Pilot Study to Evaluate the Safety and Clinical Performance of Leucopatch, an Autologous, Additive-Free, Platelet-Rich Fibrin for the Treatment of…

This prospective, uncontrolled pilot study evaluated the safety and clinical performance of Leucopatch an additive-free, autologous platelet-rich fibrin in the treatment of recalcitrant chronic wounds. Fifteen patients, with 16 lower extremity chronic wounds of varying etiologies were treated weekly with Leucopatch, prepared at the point of care from a donation of the patients’ blood, for 6 weeks, or until healing was complete. The wounds had been present for 2 to 108 months (median 24 months) and ranged in size from 0.4 to 15.7 cm 2 (median 2.3 cm 2 ) and had not responded to previous treatments

This prospective, uncontrolled pilot study evaluated the safety and clinical performance of Leucopatch an additive-free, autologous platelet-rich fibrin in the treatment of recalcitrant chronic wounds. Fifteen patients, with 16 lower extremity chronic wounds of varying etiologies were treated weekly with Leucopatch, prepared at the point of care from a donation of the patients’ blood, for 6 weeks, or until healing was complete. The wounds had been present for 2 to 108 months (median 24 months) and ranged in size from 0.4 to 15.7 cm 2 (median 2.3 cm 2 ) and had not responded to previous treatments

Continue reading here:
A Pilot Study to Evaluate the Safety and Clinical Performance of Leucopatch, an Autologous, Additive-Free, Platelet-Rich Fibrin for the Treatment of…